Pages that link to "Q31132651"
Jump to navigation
Jump to search
The following pages link to Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease (Q31132651):
Displaying 50 items.
- alpha-Synuclein and neuronal cell death (Q21202835) (← links)
- Parkinson's Disease: Genetics and Pathogenesis (Q22242000) (← links)
- Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation (Q24297619) (← links)
- Definition of a molecular pathway mediating α-synuclein neurotoxicity (Q26269832) (← links)
- M1 and M2 immune activation in Parkinson's Disease: Foe and ally? (Q27024667) (← links)
- Early Parkinson's disease symptoms in α-synuclein transgenic monkeys (Q27301058) (← links)
- Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors (Q27318127) (← links)
- Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease (Q27320553) (← links)
- Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies (Q27322513) (← links)
- The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease (Q28068464) (← links)
- Role of microRNAs in the Regulation of α-Synuclein Expression: A Systematic Review (Q28080047) (← links)
- Parkinson's disease: animal models and dopaminergic cell vulnerability (Q28080503) (← links)
- Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation (Q28477043) (← links)
- Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque (Q28554611) (← links)
- Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1 (Q28732131) (← links)
- Value of genetic models in understanding the cause and mechanisms of Parkinson's disease (Q30412016) (← links)
- Animal models of Parkinson's disease: vertebrate genetics (Q30429583) (← links)
- Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss (Q30547326) (← links)
- Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. (Q30856480) (← links)
- Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors (Q31148881) (← links)
- Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra (Q33269934) (← links)
- Detection of compounds that rescue Rab1-synuclein toxicity (Q33326182) (← links)
- Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. (Q33526342) (← links)
- Oral N-Acetyl-Cysteine Attenuates Loss of Dopaminergic Terminals in α-Synuclein Overexpressing Mice (Q33680232) (← links)
- Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates (Q33731243) (← links)
- ASIP Outstanding Investigator Award Lecture. New approaches to the pathology and genetics of neurodegeneration (Q33816233) (← links)
- Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein (Q33847712) (← links)
- Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation (Q33948478) (← links)
- Brain disposition of α-Synuclein: roles of brain barrier systems and implications for Parkinson's disease (Q33997655) (← links)
- Large animal models are critical for rationally advancing regenerative therapies (Q33999256) (← links)
- SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress (Q34081400) (← links)
- Versatile somatic gene transfer for modeling neurodegenerative diseases (Q34285870) (← links)
- Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model t (Q34321875) (← links)
- PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease (Q34441377) (← links)
- rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration (Q34465572) (← links)
- Lewy bodies (Q34478663) (← links)
- A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions (Q34612993) (← links)
- Nonhuman primate models of Parkinson's disease (Q34665820) (← links)
- A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons (Q34795038) (← links)
- Domain a' of protein disulfide isomerase plays key role in inhibiting alpha-synuclein fibril formation (Q34861594) (← links)
- Molecular insights into Parkinson's disease (Q34988753) (← links)
- Gene therapy progress and prospects: Parkinson's disease (Q35206326) (← links)
- The role of alpha-synuclein in Parkinson's disease: insights from animal models (Q35209957) (← links)
- Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. (Q35589979) (← links)
- AAV's Golden Jubilee (Q35594880) (← links)
- Using human neural stem cells to model neurological disease. (Q35634536) (← links)
- Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse (Q35675406) (← links)
- Proteomic approach to studying Parkinson's disease (Q35794541) (← links)
- Genetic clues to the pathogenesis of Parkinson's disease (Q35844782) (← links)
- Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders. (Q35877637) (← links)